ERBB2 and breast cancer: Lapuleucel-T, consisting of an adoptive transfer of autologous antigen-presenting cells activated in vitro with a recombinant fusion protein comprising HER-2 sequences, demonstrated safety and significant antitumor immune response in patients with HER-2-overexpressing metastatic BC, associated with clinical response or disease stabilization in some patients (112).